The National Institute for Health and Care Excellence (NICE) has recommended obecabtagene autoleucel (obe-cel) for adults aged 26 and older with relapsed or refractory B-cell precursor acute ...
News-Medical.Net on MSN
Epigenetic plasticity in germinal center B cells may help explain lymphoma origins
Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...
More than a third of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with the CAR T-cell therapy obecabtagene autoleucel (obe-cel) remained in remission at a ...
Obecabtagene autoleucel showed effective outcomes in both younger and older adults with relapsed/refractory B-cell acute lymphoblastic leukemia, with similar remission rates and chimeric antigen ...
Hosted on MSN
B-Cell Acute Lymphoblastic Leukemia for Adults: Causes, Symptoms, Diagnosis and Treatment
B-Cell Acute Lymphoblastic Leukemia for Adults: Causes, Symptoms, Diagnosis and Treatment: By Shreoshree Chakrabarty B-Cell Acute Lymphoblastic Leukemia (B-ALL) is a rare but aggressive form of ...
Using CD22/CD19 CAR T-cell therapy followed by autologous stem cell transplant (ASCT) showed promising results in patients with Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic ...
THOUSAND OAKS, Calif., Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback